Generic Name and Formulations:
Baclofen 50mcg/mL, 500mcg/mL, 1000mcg/mL, 2000mcg/mL; for intrathecal inj; preservative-free.
Indications for GABLOFEN:
Severe spasticity of cerebral or spinal origin, when oral baclofen is not appropriate.
Adults and Children:
<4yrs: not established. ≥4yrs: Give test dose 1st by intrathecal inj via spinal catheter or lumbar puncture (see full labeling for dose and timing; use 50mcg/mL syringe). Dose titration: see full labeling. Maintenance: titrate individually; use lowest effective dose; maintain some degree of muscle tone. Spinal cord origin: usually 300–800mcg/day. Cerebral origin: usually 90–700mcg/day (24–1199mcg/day in <12yrs). Avoid abrupt cessation (may be severe/fatal); closely monitor pump, alarms, and refill schedule; wean orally-administered antispasticity drugs carefully.
Not for IV, IM, SC or epidural administration.
Abrupt discontinuation may result in high fever, altered mental status, rebound spasticity, muscle rigidity; avoid. Apparent risk patients (eg, spinal cord injury at T-6 or higher, communicative impairment, history of withdrawal symptoms): closely monitor infusion system, dosing schedule, refills, pump alarms, clinical signs of withdrawal or overdose. Avoid use of prefilled syringe in an aseptic setting to fill pumps prior to implantation. Supervise 1st dose, during titration and refills; have resuscitative equipment and trained personnel available. Do not use chronically if test dose ineffective. For chronic dosing use approved pump (eg, Medtronic SynchroMed II Programmable). Allow at least one year after traumatic brain injury before starting. Psychosis. Schizoaffective disorders. Confusion. Autonomic dysreflexia. Infections. Hospitalize immediately if pump malfunction suspected. Pregnancy (Cat.C). Nursing mothers: not recommended.
Hypotension, dyspnea with morphine. Additive CNS depression with alcohol, other CNS depressants. Do not mix with other drugs in pump or catheter. Physostigmine may be useful in reversing effects (see full labeling).
Muscle relaxant (central), antispastic agent.
Hypotonia, somnolence, dizziness, paresthesia, nausea, headache, constipation, convulsion, hypotension, coma, drowsiness, psychosis, confusion, agitation, leukocytosis, chills, urinary retention; CNS depression, cardiovascular collapse, respiratory failure; others.
Prefilled syringes (50mcg/1mL, 10000mcg/20mL, 20000mcg/20mL, 40000mcg/20mL)—1; Vials (10000mcg/20mL, 20000mcg/20mL, 40000mcg/20mL)—1
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Prediabetes a Useful Indicator for Cardiovascular and Renal Risks